Laborie, a subsidiary within
In 2020, Laborie entered into a strategic partnership with Urotronic, whereby Laborie acquired 9 percent of the company and two separate call options, one for OptilumeTM urethral strictures, and one for the acquisition of the remaining 91 percent of Urotronic, including OptilumeTM BPH.
In early 2022, Laborie exercised its call option to acquire OptilumeTM urethral strictures. Since the acquisition, Laborie's strong launch execution and the product's good clinical performance have driven robust revenue growth.
Now acquiring Urotronic, including the OptilumeTM BPH product, Laborie will pay
In conjunction with the Urotronic acquisition, Laborie will also make a
"Growing our great platform companies within
"We are delighted to welcome the Urotronic team to Laborie. Laborie is committed to improving outcomes for patients suffering from urological disorders by creating and advancing innovative technologies that help restore dignity and quality of life", comments Laborie CEO
Laborie anticipates making significant investments in commercialization and clinical programs for OptilumeTM BPH in order to successfully launch and grow the product, which is expected to result in initial dilution to Laborie's earnings and significant accretion thereafter.
About Optilume BPH
OptilumeTM BPH is a drug-coated balloon with strong clinical data that provides a highly differentiated, minimally invasive treatment option for BPH physicians and patients. It is the only commercially available minimally invasive BPH medical product with both a device and drug mechanism of action, and represents a paradigm change from the methods currently used by urologists to treat this condition.
Laborie is a global medical technology company focused on Urology, Urogynecology, Gastroenterology, Obstetrics,
For further information:
Phone +46 70 550 3500
Magnus Dalhammar, Head of Investor Relations,
Phone +46 73 524 2130
Our press releases can be accessed at www.investorab.com
Investor, founded by the Wallenberg family in 1916, is an engaged owner of high quality global companies. We have a long-term investment perspective. Through board participation, as well as industrial experience, our network and financial strength, we work continuously to support our companies to remain or become best-in-class. Our holdings include, among others,
(c) 2023 Cision. All rights reserved., source